![]() |
市場調査レポート
商品コード
1351092
疱疹状皮膚炎の2030年までの市場予測:治療、投与経路、流通チャネル、地域別の世界分析Dermatitis Herpetiformis Market Forecasts to 2030 - Global Analysis By Treatment (Therapeutics, Dietary and Other Treatments), Route of Administration, Distribution channel and By Geography |
||||||
カスタマイズ可能
|
疱疹状皮膚炎の2030年までの市場予測:治療、投与経路、流通チャネル、地域別の世界分析 |
出版日: 2023年09月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 175+ Pages
納期: 2~3営業日
|
Stratistics MRCによると、世界の疱疹状皮膚炎市場は予測期間中にCAGR 9.2%で成長しています。
疱疹状皮膚炎は、強いかゆみと灼熱感を特徴とする慢性の自己免疫疾患で、皮膚に発疹が生じる。グルテン過敏性腸症やグルテン消化異常であるセリアック病の患者が頻繁に発症します。疫学的には、主に若年成人が罹患するまれな疾患です。最終的な治療法は、厳格なグルテン除去食で、数カ月で皮膚の改善が期待できるが、グルテン除去食が唯一の治療法となるには数年かかるかもしれないです。
DermNet NZによると、15歳から40歳までの患者が発症する可能性があります。男性は女性よりも罹患しやすいです。
疱疹状皮膚炎は激しいかゆみを伴う。長期にわたる自己免疫疾患であり、強いかゆみ、ほてり、皮疹が生じる。セリアック病、グルテン過敏性腸症、グルテンの消化に問題がある人がなりやすいです。疫学によれば、ほとんどが若年成人に発症するまれな病気です。ここでも、疱疹状皮膚炎の治療法を見つけるための投資が増加しているため、市場の急成長が期待されています。
しかし、患者は歯の問題を経験する可能性があります。さらに、疱疹状皮膚炎が疥癬と間違われる可能性もあります。治療薬のため、患者は貧血、骨粗鬆症、1型糖尿病、甲状腺の問題にも悩まされます。珍しい問題もあるが、運動失調や神経障害などの神経症状を引き起こす可能性もあります。ヘモグロビンの低下といったダプソン使用による悪影響は、喉の痛み、失神発作、めまい、さらには人によっては肝臓障害を引き起こす可能性があり、市場拡大を制限するもう一つの理由となっています。
皮膚炎の罹患率の増加や新興国市場における有利な償還政策も、市場成長率に寄与すると予想されます。さらに、より良い、より経済的な治療を提供するための政府の取り組みや、この疾患の治療オプションに対する認知度の向上も、世界市場に影響を与えると予想されます。
同市場は、治療費の高さによって大きな制約を受けています。患者は、処方薬や健康診断の受診を含む長期的なケアにかかる費用によって負担を強いられる可能性があり、これが最善の治療選択肢を利用する妨げとなる可能性があります。さらに、ジェネリック治療の選択肢の出現と厳しい規制上の制約により、業界は大きな影響を受けると予測されます。
コロナウイルス危機とそれに続く世界数カ国の封鎖は、主要な尿素サイクル障害治療企業に財政的な影響を与えています。さらに、民間ヘルスケア部門はパンデミックが最もダメージを与えた分野の一つです。パンデミックは、研究開発、生産、医薬品供給に関する世界市場に悪影響を与えました。加えて、一部の国では政府の閉鎖により、パンデミックは世界中の様々な企業の製薬産業の拡大に影響を及ぼしています。
予測期間中、外用薬セグメントが最大となる見込みです。外用処方薬は通常、疱疹状皮膚炎の治療の第一選択薬です。これらはローション、クリーム、坐薬などの形状になります。このような即時性は、迅速な獲得と実質的な行動維持につながり、市場のセグメント成長を促進すると予想されます。
予測期間中、小売薬局セグメントは最も高いCAGRが見込まれます。疱疹状皮膚炎の治療薬は、一般的に小売薬局でジェネリック医薬品として入手可能です。また、小売薬局では、自宅へのドラッグデリバリーや、幅広い種類の医薬品・薬剤の入手といった便利なサービスが提供されています。さらに、脂質調整薬市場の拡大は、多忙なライフスタイルやストレスの多い仕事のスケジュールにより、製品を迅速に入手したいという消費者の需要によって後押しされると予想されます。
北米は、遺伝性疾患や遺伝子変異関連疾患の増加により、予測期間中最大の市場シェアを占めると予測されます。これは主に、アトピー性皮膚炎の有病率の増加、患者層における治療意識の高さ、アトピー性皮膚炎産業の進歩に起因しています。また、製薬企業による新薬開発への取り組みが活発化していること、技術的進歩が見られること、採用率が高いことなども、患者がより良い治療を選択するのに役立っています。
アジア太平洋地域は、患者の認知度が低いため、予測期間中に最も高いCAGRを維持すると予測されます。この背景には、急速に発展するヘルスケア技術の存在感、膨大な患者数、医療費の増加があります。各国の研究開発プロジェクトの増加、医療インフラの開発、技術的に高度な外科手術の受け入れの増加、政府のイニシアチブの高まりにより、予測期間中に市場は成長を示すと予想されます。
According to Stratistics MRC, the Global Dermatitis Herpetiformis Market is growing at a CAGR of 9.2% during the forecast period. Dermatitis Herpetiformis is a chronic autoimmune illness marked by strong itching and burning sensations, resulting in a skin rash. People with celiac disease, a gluten-sensitive enteropathy or anomaly in gluten digestion, frequently have it. Epidemiologically speaking, it is a rare disease that primarily affects young adults. The final course of treatment entails a strict gluten-free diet, with which skin improvement is anticipated in a few months, though it might take years for the gluten-free diet to be the only course of treatment.
According to the DermNet NZ organisation, Patients between the ages of 15 and 40 may be affected. Males are more susceptible to the condition than females.
Patients with dermatitis herpetiformis have severe itching. It is a long-term autoimmune condition that results in intense itchiness, burning, and skin rashes. People with celiac disease, gluten-sensitive enteropathy, or issues with gluten digestion are more likely to experience it. It is a rare disease that mostly affects young adults, according to epidemiology. Again, due to increasing investments in finding treatments for dermatitis herpetiformis, the market is expected to grow rapidly.
Patients could, however, experience dental issues. Additionally, it's possible that dermatitis herpetiformis will be mistaken for scabies. Due to therapeutic medications, the patient also suffers anemia, osteoporosis, Type 1 diabetes, and thyroid issues. Although some of the problems are uncommon, there is a potential that they could result in neurological conditions including ataxia and neuropathy. The negative consequences of dapsone use, such as a drop in hemoglobin, which can cause sore throats, fainting spells, dizziness, and even liver problems in some people, are another reason that can limit market expansion.
The increasing incidence of dermatitis and the favorable reimbursement policies in developing nations are also anticipated to contribute to the market growth rate. Additionally, it is anticipated that increased government efforts to provide better and more economical care as well as increased awareness of the disease's treatment options will have an impact on the global market.
The market is severely constrained by the treatment's high cost. Patients may be burdened by the costs of long-term care, which may include prescription drugs and wellness visits, and this may prevent them from accessing the best possible treatment options. Furthermore, it is projected that the industry will be significantly impacted by the advent of generic treatment options and strict regulatory constraints.
The corona virus crisis and subsequent lockdown in several nations worldwide have financially impacted major urea cycle disorders treatment firms. Moreover, the private healthcare sector is one of the areas that the pandemic has damaged the most. The pandemic has had a detrimental impact on the worldwide market regarding research and development, production, and pharmaceutical supply. In addition, due to government lockdowns in some countries, the pandemic has impacted the expansion of pharmaceutical industries of various corporations worldwide.
The topical segment is expected to be the largest during the forecast period. A topical prescription drug is usually the first line of treatment for dermatitis herpetiformis. These can be in the shape of lotions, creams, suppositories, and other things. Such immediacy leads to speedy acquisition and substantial behaviour maintenance, which is expected to drive segment growth in the market.
The retail pharmacies segment is expected to have the highest CAGR during the forecast period. Medication for dermatitis herpetiformis is commonly available as a generic pharmaceutical in retail pharmacies. In addition, retail pharmacies provide convenient services such as medicine delivery to your home and the availability of a wide range of drugs and medicines. Furthermore, lipid-regulating medicines market expansion is expected to be boosted by consumer demand for quick availability of products due to busy lifestyles and stressful work schedules.
North America is projected to hold the largest market share during the forecast period, owing to increased inherited and genetic mutation related disorders. This is primarily attributed to increasing prevalence of atopic dermatitis, high treatment awareness among the patient population, and advancement in atopic dermatitis industry. The increasing initiatives taken by the pharmaceutical organizations to generate novel drugs, technological advancements and high adoption rate, which will help patients opt for better treatment.
Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the low awareness among patients. This is attributed to strong presence of rapidly developing healthcare technology, huge patient population and rise in healthcare expenditure. With the rise in R&D projects in countries, developing medical infrastructure, rise in acceptance of technologically advanced surgical procedures and rising government initiatives, the market is expected to witness growth over forecast period.
Some of the key players in Dermatitis Herpetiformis market include: Allergan, 3B scientific, Acros Organics, Aidance Scientific, AlliChem, Aidance Scientific, Canyon Bakehouse, GlaxoSmithKline Pharmaceuticals Ltd., HBC Chem, Ivy Fine chemicals, Nostrum Laboratories Inc., Pfizer Inc., Shingles Skincare, AbbVie Inc. and Waterstone Technology.
In May 2023, AbbVie's aesthetics unit is growing its product catalog once again with a new FDA approval. The product, called Skinvive, nabbed an FDA nod this week and falls within Allergan's Juvederm dermal filler collection.
In May 2022, Sidekick and Pfizer launch digital therapeutics solution for Atopic Dermatitis. The solution will be rolled-out in the UK first, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan.
In January 2022, AbbVie Inc. announced that the US FDA has approved RINVOQ (upadacitinib) for the treatment of severe atopic dermatitis in children and adults 12 years of age and older. RINVOQ is recommended for patients who have not responded to previous injection or tablet treatments.